Arcoma AB
Research Arcoma AB (ARCOMA) on Bullrun: valuation model: 11.0% overvalued, market cap SEK 105.31M, P/E 27.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerARCOMA
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryMedical Devices
- CurrencySEK
- Valuation signal11.0% overvalued
- Market capSEK 105.31M
- P/E27.3
- Financial periodQ1 2026
- RevenueSEK 31.13M
- Net incomeSEK 811.00K
- Free cash flow-SEK 1.43M
- Gross margin40.0%
Valuation Snapshot
Bullrun's latest valuation model marks Arcoma AB as 11.0% overvalued; latest market cap is SEK 105.31M; P/E is 27.3.
Peer valuation comparison
Latest P/E is 27.26x versus a Healthcare sector median of 24.64x (10.6% above).
Latest P/E is 27.26x versus a Sweden median of 18.18x (49.9% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 131.13M | SEK 5.04M | n/a | 40.9% | n/a | SEK 35.32M | SEK 0 | SEK 74.73M |
| FY2024 | SEK 159.10M | SEK 12.74M | n/a | 40.8% | n/a | SEK 13.38M | SEK 0 | SEK 59.33M |
| FY2023 | SEK 166.00M | SEK 2.56M | n/a | 36.7% | n/a | SEK 5.00M | n/a | n/a |
| FY2022 | SEK 129.89M | SEK 1.90M | n/a | 42.6% | n/a | SEK 9.66M | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-09-30 | SEK 105.31M | 27.3 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Arcoma AB
Arcoma AB develops, produces, and provides radiology solutions and digital x-ray systems in Sweden and internationally. The company offers solutions for x-ray systems covering radiological applications and general, eneral, muscle/skeleton, thoratic, pediatric, and trauma/resus clinics. It also provides x-ray detectors; video bank;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Arcoma AB overvalued or undervalued?
Bullrun's valuation model currently marks Arcoma AB as 11.0% overvalued.
What is Arcoma AB's market cap?
Arcoma AB's market capitalization is SEK 105.31M.
What is Arcoma AB's P/E ratio?
Arcoma AB's price-to-earnings (P/E) ratio is 27.3.
What does Arcoma AB do?
Arcoma AB develops, produces, and provides radiology solutions and digital x-ray systems in Sweden and internationally. The company offers solutions for x-ray systems covering radiological applications and general, eneral, muscle/skeleton, thoratic, pediatric, and trauma/resus clinics.